Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Rating Reaffirmed by Needham & Company LLC

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Needham & Company LLC in a research report issued on Wednesday, Benzinga reports. They currently have a $220.00 target price on the specialty pharmaceutical company’s stock. Needham & Company LLC’s target price points to a potential upside of […]

Leave a Reply

Your email address will not be published.

Previous post Illumina (NASDAQ:ILMN) Stock Rating Reaffirmed by OTR Global
Next post Raymond James Boosts Aritzia (OTCMKTS:ATZAF) Price Target to $46.00